Therapeutic efficacy of fuzheng-huayu tablet based traditional Chinese medicine syndrome differentiation on hepatitis-B-caused cirrhosis: A multicenter double-blind randomized controlled trail

Evidence-based Complementary and Alternative Medicine

Volumn 2013, Issue , 2013, Pages

  Song, Ya Nan ^a   Sun, Ji Jia ^a   Lu, Yi Yu ^a   Xu, Lie Ming ^b   Gao, Yue Qiu ^b   Zhang, Wei ^a   Wang, Xiao Su ^c   Xue, Dong Ying ^d   Zheng, Qing Shan ^a   Su, Shi Bing ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Shuguang Hospital   (China)

^c Shanghai Yueyang Hospital   (China)

^d Department of Medical Imaging   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHINESE DRUG; FUZHENG HUAYU TABLET; HYALURONIC ACID; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BAYES THEOREM; CHILD PUGH SCORE; CHINESE MEDICINE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B CAUSED CIRRHOSIS; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRADITIONAL MEDICINE;

EID: 84875510641     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2013/709305     Document Type: Article

References (28)

1. McMahon B. J., Epidemiology and natural history of hepatitis B. Seminars in Liver Disease 2005 25 supplement 1 3 8 2-s2.0-24344435917 10.1055/s-2005-915644 (Pubitemid 41254588)
2. Margolis H. S., Alter M. J., Hadler S. C., Hepatitis B: evolving epidemiology and implications for control. Seminars in Liver Disease 1991 11 2 84 92 2-s2.0-0025892665
3. de Jongh F. E., Janssen H. L. A., De Man R. A., Hop W. C. J., Schalm S. W., Van Blankenstein M., Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992 103 5 1630 1635 2-s2.0-0026658646
4. Hu Y. Y., Liu P., Liu C., Investigation on indication of fuzheng huayu capsule against hepatic fibrosis and its non-invasive efficacy evaluation parameters: data analysis of liver biopsy of 50 patients with chronic hepatitis B before and after treatment. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi 2006 26 1 18 22 2-s2.0-38049062629
5. Liu P., Liu C., Xu L. M., Hu Y. Y., Xue H. M., Liu C. H., Zhang Z. Q., Effects of Fuzheng Huayu 319 recipe on liver fibrosis in chronic hepatitis B. World Journal of Gastroenterology 1998 4 1-6 348 353 2-s2.0-0000620074 (Pubitemid 128620188)
6. Liu P., Hu Y. Y., Liu C., Xu L. M., Liu C. H., Sun K. W., Hu D. C., Yin Y. K., Zhou X. Q., Wan M. B., Cai X., Zhang Z. Q., Ye J., Tang B. Z., He J., Multicenter clinical study about the action of Fuzheng Huayu Capsule against liver fibrosis with chronic hepatitis B. Zhong xi Yi Jie he Xue Bao 2003 1 2 89 102 2-s2.0-16544386662
7. Liu P., Wu D. Z., Liu C. H., Mechanism study on combination of Chinese herbal formula to support anti-pathogenic ability and dissipate blood stasis in promoting reversion of liver fibrosis in CCl4 Rats. Shang Hai Zhong Yi Yao Da Xue Xue Bao 2002 16 1 37 41
8. Jiang C. M., Liu C. H., Liu C., Inhibiting effect of Fuzhenghuayu Capsule on the activation of hepatic satellite cells in rats. Zhong Guo Zhong Xi Yi Jie He Za Zhi 2003 11 5 280 283
9. Lu X., Ping L., Liu C. H., Experimental study for Role of Fu Zheng Hua Yu recipe on promoting reversion of hepatic sinusoid capillarization induced by dimethylnitrosamine in rats. Zhong Yi Za Zhi 2003 44 136 139
10. Dai J., Sun S., Cao H., Applications of new technologies and new methods in ZHENG differentiation. Evidence-Based Complementary and Alternative Medicine 2012 2012 8 298014 10. 1155/2012/298014
11. Sun Y. N., Ning S. Y., Lu M. Y., Chinese traditional medical clinical diagnosis for coronary heart disease based on Bayes classification. Applied Computer Research 2006 11 164 166
12. Wang M., Zhang P., Wang Y., Study on the prediction of Chinese medicine component function based on pharmacological effects. World Science and Technology-Modernization of Traditional Chinese Medicine 2011 13 1 93 95
13. Mulrow C. D., Williams J. W. Jr., Trivedi M., Treatment of depression-newer pharmacotherapy. Psychopharmacology Bulletin 1998 34 4 409 795
14. Wright D. F. B., Duffull S. B., Development of a bayesian forecasting method for warfarin dose individualisation. Pharmaceutical Research 2011 28 5 1100 1111 2-s2.0-79955576111 10.1007/s11095-011-0369-x
15. Chinese Association of Integrative Medicine, Liver Disease Committee, Guideline for the diagnosis and treatment of liver fibrosis with integrative Medicine. Zhong Xi Yi Jie He Xue Bao 2006 4 6 551 555
16. Wang Q. L., Yuan J. L., Tao Y. Y., Zhang Y., Liu P., Liu C. H., Fuzheng Huayu recipe and vitamin E reverse renal interstitial fibrosis through counteracting TGF- β 1-induced epithelial-to-mesenchymal transition. Journal of Ethnopharmacology 2010 127 3 631 640 2-s2.0-76149139723 10.1016/j.jep.2009.12.011
17. Cholongitas E., Papatheodoridis G. V., Vangeli M., Systematic review: the model for end-stage liver disease-should it replace Child-Pughh's classification for assessing prognosis in cirrhosis? Alimentary Pharmacology and Therapeutics Aims 2005 22 11-12 1079 1089 10.1111/j.1365-2036.2005.02691.x (Pubitemid 41779515)
18. Christensen E., Prognosticmodels including the Child-Pughh, MELD and Mayo risk scores-where are we and where should we go? Journal of Hepatology 2004 41 2 344 350 10.1016/j.jhep.2004.06.005 (Pubitemid 39177643)
19. Zheng X., Guidline For Clinical New Drug Research in Chinese Herbal Medicine 2002 Beijing, China Chinese Medical Science and Technology Press
20. Andrés-Ferrer J., Juan A., Constrained domain maximum likelihood estimation for naive Bayes text classification. Pattern Analysis and Applications 2010 13 2 189 196 2-s2.0-77951765063 10.1007/s10044-009-0149-y
21. Cheong J. Y., Um S. H., Seo Y. S., A practical scoring system for predicting cirrhosis in patients with chronic viral hepatitis. Hepatogastroenterology 2012 59 120 2592 2597
22. Sheron N., Moore M., Ansett S., Developing a "traffic light" test with potential for rational early diagnosis of liver fibrosis and cirrhosis in the community. British Journal of General Practice 2012 62 602 e616 e624 10.3399/bjgp12X654588
23. Triantos C., Zisimopoulos K., Tsochatzis E., 207 meld vs cps for prognosis in cirrhosis. Results from a multicentre study. Journal of Hepatology 2010 52 S89
24. Li D. T., Ling C. Q., Lang Q. B., Construction of a therapeutic effect evaluation system for patients with primary liver cancer based on syndrome differentiation in traditional Chinese medicine. Zhong Xi Yi Jie He Xue Bao 2007 5 1 15 22
25. Husein H. F., Alavian S. M., Heshmat R., The efficacy of Liv-52 on liver cirrhotic patients: a randomized, double-blind, placebo-controlled first approach. Phytomedicine 2005 12 9 619 624 10.1016/j.phymed.2004.10.003 (Pubitemid 41169807)
26. Wen R., Wang J., Chen M., Chinese medicine Jiangganlong combined with anti-virus medicine in long-term treatment of active liver cirrhosis and its effect on prognosis of patients. World Journal of Gastroenterology 2006 14 29 2860 2864 (Pubitemid 44831484)
27. Zhao C. Q., Gu H. T., Cheng Y., et A., Applying Fuzheng Huayu Gantang comprehensive therapeutic program for treatment of post-hepatitis B liver cirrhosis complicated with glyco-metabolic abnormality. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe Zazhi 2008 28 1 24 27 2-s2.0-55949102897
28. Xue M., Chen K. J., Ma X. J., Liu J. G., Jiang Y. R., Miao Y., Yin H. J., Effects of Xuefu Zhuyu Oral Liquid on hemorheology in patients with blood-stasis syndrome due to coronary disease and their relationship with human platelet antigen-3 polymorphism. Journal of Chinese Integrative Medicine 2008 6 11 1129 1135 2-s2.0-56849107262 10.3736/jcim20081106